JP2017530950A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017530950A5 JP2017530950A5 JP2017511242A JP2017511242A JP2017530950A5 JP 2017530950 A5 JP2017530950 A5 JP 2017530950A5 JP 2017511242 A JP2017511242 A JP 2017511242A JP 2017511242 A JP2017511242 A JP 2017511242A JP 2017530950 A5 JP2017530950 A5 JP 2017530950A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- lymphoma
- medicament
- cell
- alk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 claims 17
- 206010028980 Neoplasm Diseases 0.000 claims 16
- 201000011510 cancer Diseases 0.000 claims 13
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 claims 8
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 claims 8
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 8
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 8
- 239000002146 L01XE16 - Crizotinib Substances 0.000 claims 7
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical group O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 claims 7
- 229960005061 crizotinib Drugs 0.000 claims 7
- 229940122531 Anaplastic lymphoma kinase inhibitor Drugs 0.000 claims 6
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 6
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 6
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 6
- 229940124060 PD-1 antagonist Drugs 0.000 claims 6
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 6
- 238000003364 immunohistochemistry Methods 0.000 claims 6
- 229960002621 pembrolizumab Drugs 0.000 claims 5
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 4
- 208000017604 Hodgkin disease Diseases 0.000 claims 4
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 4
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 4
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 4
- 206010041067 Small cell lung cancer Diseases 0.000 claims 4
- 238000003556 assay Methods 0.000 claims 4
- 239000002775 capsule Substances 0.000 claims 4
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 4
- 241000282412 Homo Species 0.000 claims 3
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 208000003950 B-cell lymphoma Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 101000779641 Homo sapiens ALK tyrosine kinase receptor Proteins 0.000 claims 2
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 claims 2
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 102000051965 human ALK Human genes 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 210000003292 kidney cell Anatomy 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 210000003887 myelocyte Anatomy 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462041288P | 2014-08-25 | 2014-08-25 | |
| US62/041,288 | 2014-08-25 | ||
| PCT/US2015/046477 WO2016032927A1 (en) | 2014-08-25 | 2015-08-24 | Combination of a pd-1 antagonist and an alk inhibitor for treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020067185A Division JP2020117524A (ja) | 2014-08-25 | 2020-04-03 | 癌を処置するためのｐｄ−１アンタゴニストおよびａｌｋ阻害剤の併用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017530950A JP2017530950A (ja) | 2017-10-19 |
| JP2017530950A5 true JP2017530950A5 (enExample) | 2018-09-20 |
Family
ID=54035336
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017511242A Withdrawn JP2017530950A (ja) | 2014-08-25 | 2015-08-24 | 癌を処置するためのｐｄ−１アンタゴニストおよびａｌｋ阻害剤の併用 |
| JP2020067185A Pending JP2020117524A (ja) | 2014-08-25 | 2020-04-03 | 癌を処置するためのｐｄ−１アンタゴニストおよびａｌｋ阻害剤の併用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020067185A Pending JP2020117524A (ja) | 2014-08-25 | 2020-04-03 | 癌を処置するためのｐｄ−１アンタゴニストおよびａｌｋ阻害剤の併用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10695426B2 (enExample) |
| EP (1) | EP3185866A1 (enExample) |
| JP (2) | JP2017530950A (enExample) |
| CA (1) | CA2955676A1 (enExample) |
| WO (1) | WO2016032927A1 (enExample) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2170959T1 (sl) | 2007-06-18 | 2014-04-30 | Merck Sharp & Dohme B.V. | Protitelesa proti receptorjem pd-1 za humano programirano smrt |
| LT3081576T (lt) | 2013-12-12 | 2019-10-25 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antikūnas, antigeną surišantis jo fragmentas ir jų medicininis pritaikomumas |
| EP3102604B1 (en) | 2014-02-04 | 2020-01-15 | Pfizer Inc | Combination of a pd-1 antagonist and a 4-1bb agonist for treating cancer |
| EP3185866A1 (en) * | 2014-08-25 | 2017-07-05 | Pfizer Inc. | Combination of a pd-1 antagonist and an alk inhibitor for treating cancer |
| US10800846B2 (en) | 2015-02-26 | 2020-10-13 | Merck Patent Gmbh | PD-1/PD-L1 inhibitors for the treatment of cancer |
| US10869924B2 (en) | 2015-06-16 | 2020-12-22 | Merck Patent Gmbh | PD-L1 antagonist combination treatments |
| CN108368170B (zh) | 2015-07-13 | 2022-04-15 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
| US11453697B1 (en) | 2015-08-13 | 2022-09-27 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
| US11072657B2 (en) * | 2015-11-18 | 2021-07-27 | Bristol-Myers Squibb Company | Treatment of lung cancer using a combination of an anti-PD-1 antibody and an anti-CTLA-4 antibody |
| WO2018027524A1 (en) * | 2016-08-09 | 2018-02-15 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibody formulation |
| AU2017325866B2 (en) | 2016-09-15 | 2021-09-09 | Leidos, Inc. | PD-1 peptide inhibitors |
| US10799555B2 (en) | 2016-09-15 | 2020-10-13 | Leidos, Inc. | PD-1 peptide inhibitors |
| IL265762B2 (en) | 2016-10-06 | 2024-04-01 | Merck Patent Gmbh | Dosing regimen of avelumab for the treatment of cancer |
| RU2019122602A (ru) * | 2016-12-20 | 2021-01-22 | Мерк Шарп И Доум Корп. | Комбинации антагонистов pd-1 и циклических динуклеотидных агонистов sting для лечения рака |
| RU2769132C2 (ru) | 2017-01-10 | 2022-03-28 | Новартис Аг | Фармацевтическая комбинация, содержащая ингибитор alk и ингибитор shp2 |
| KR102644408B1 (ko) | 2017-03-30 | 2024-03-07 | 메르크 파텐트 게엠베하 | 암의 치료를 위한 항-pd-l1 항체 및 dna-pk 억제제의 병용 |
| EP3630807B1 (en) | 2017-05-25 | 2025-08-13 | Leidos, Inc. | Pd-1 and ctla-4 dual inhibitor peptides |
| AU2018311965A1 (en) | 2017-08-04 | 2020-02-13 | Merck Sharp & Dohme Llc | Combinations of PD-1 antagonists and benzo[b]thiophene sting antagonists for cancer treatment |
| JP2020530838A (ja) | 2017-08-04 | 2020-10-29 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | がん治療のためのベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニスト |
| TW201923089A (zh) | 2017-11-06 | 2019-06-16 | 美商建南德克公司 | 癌症之診斷及治療方法 |
| WO2019160751A2 (en) * | 2018-02-13 | 2019-08-22 | Merck Sharp & Dohme Corp. | Methods for treating cancer with anti-pd-1 antibodies |
| KR20200119845A (ko) * | 2018-02-13 | 2020-10-20 | 머크 샤프 앤드 돔 코포레이션 | 항 pd-1 항체 및 항 ctla4 항체를 사용한 암의 치료 방법 |
| DK3758732T3 (da) | 2018-02-27 | 2024-10-07 | Leidos Inc | PD-1-peptidinhibitorer |
| TWI841554B (zh) | 2018-03-21 | 2024-05-11 | 丹麥商珍美寶股份有限公司 | 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法 |
| UA130009C2 (uk) * | 2018-05-07 | 2025-10-15 | Генмаб А/С | Спосіб лікування раку за допомогою комбінації антитіла до pd-1 і кон'югата антитіла до тканинного фактора і лікарського засобу |
| AU2019288728A1 (en) | 2018-06-23 | 2021-01-14 | Genentech, Inc. | Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor |
| JP2021530502A (ja) | 2018-07-18 | 2021-11-11 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニスト、代謝拮抗剤、及びプラチナ製剤で肺がんを治療する方法 |
| CN112805267B (zh) | 2018-09-03 | 2024-03-08 | 豪夫迈·罗氏有限公司 | 用作tead调节剂的甲酰胺和磺酰胺衍生物 |
| TWI844571B (zh) | 2018-10-30 | 2024-06-11 | 丹麥商珍美寶股份有限公司 | 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法 |
| AU2020208193A1 (en) | 2019-01-14 | 2021-07-29 | BioNTech SE | Methods of treating cancer with a PD-1 axis binding antagonist and an RNA vaccine |
| TW202043291A (zh) | 2019-04-19 | 2020-12-01 | 美商建南德克公司 | 抗mertk抗體及使用方法 |
| AU2020279371A1 (en) | 2019-05-22 | 2021-12-23 | Leidos, Inc. | LAG 3 binding peptides |
| GB201915618D0 (en) * | 2019-10-28 | 2019-12-11 | Univ Oslo | ALK inhibitors for treatment of ALK-negative cancer and antibody-mediated diseases |
| JP7629916B2 (ja) | 2019-11-13 | 2025-02-14 | ジェネンテック， インコーポレイテッド | 治療用化合物および使用方法 |
| EP4096708A1 (en) | 2020-01-31 | 2022-12-07 | Genentech, Inc. | Methods of inducing neoepitope-specific t cells with a pd-1 axis binding antagonist and an rna vaccine |
| US11338040B2 (en) | 2020-06-04 | 2022-05-24 | Leidos, Inc. | Immunomodulatory compounds |
| US11787775B2 (en) | 2020-07-24 | 2023-10-17 | Genentech, Inc. | Therapeutic compounds and methods of use |
| JP2023536466A (ja) | 2020-07-31 | 2023-08-25 | レイドス， インコーポレイテッド | Ｌａｇ３結合ペプチド |
| CN116261455B (zh) * | 2020-09-25 | 2024-11-01 | 苏州亚盛药业有限公司 | 一种药物组合物及其在治疗癌症中的用途 |
| AU2021361844A1 (en) | 2020-10-12 | 2023-06-15 | Leidos, Inc. | Immunomodulatory peptides |
| TW202233671A (zh) | 2020-10-20 | 2022-09-01 | 美商建南德克公司 | Ｐｅｇ結合抗ｍｅｒｔｋ抗體及其使用方法 |
| WO2022093981A1 (en) | 2020-10-28 | 2022-05-05 | Genentech, Inc. | Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists |
| AU2021374592A1 (en) | 2020-11-04 | 2023-06-01 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| EP4240766A2 (en) | 2020-11-04 | 2023-09-13 | Genentech, Inc. | Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies |
| JP7762198B2 (ja) | 2020-11-04 | 2025-10-29 | ジェネンテック， インコーポレイテッド | 抗ｃｄ２０／抗ｃｄ３二重特異性抗体及び抗ｃｄ７９ｂ抗体薬物コンジュゲートによる処置のための投与 |
| MX2023006488A (es) | 2020-12-02 | 2023-06-20 | Genentech Inc | Procedimientos y composiciones para el tratamiento neoadyuvante y adyuvante del carcinoma urotelial. |
| AU2021443318A1 (en) | 2021-04-30 | 2023-09-07 | F. Hoffmann-La Roche Ag | Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate |
| JP2024516230A (ja) | 2021-04-30 | 2024-04-12 | ジェネンテック， インコーポレイテッド | がんのための治療及び診断方法並びに組成物 |
| JP2024525381A (ja) | 2021-07-02 | 2024-07-12 | ジェネンテック， インコーポレイテッド | がんを治療するための方法及び組成物 |
| EP4377350A2 (en) | 2021-07-28 | 2024-06-05 | Genentech, Inc. | Methods and compositions for treating cancer |
| EP4377351A1 (en) | 2021-07-28 | 2024-06-05 | F. Hoffmann-La Roche AG | Methods and compositions for treating cancer |
| TW202321308A (zh) | 2021-09-30 | 2023-06-01 | 美商建南德克公司 | 使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法 |
| WO2023080900A1 (en) | 2021-11-05 | 2023-05-11 | Genentech, Inc. | Methods and compositions for classifying and treating kidney cancer |
| WO2023097195A1 (en) | 2021-11-24 | 2023-06-01 | Genentech, Inc. | Therapeutic indazole compounds and methods of use in the treatment of cancer |
| US12275745B2 (en) | 2021-11-24 | 2025-04-15 | Genentech, Inc. | Therapeutic compounds and methods of use |
| IL313361A (en) * | 2021-12-06 | 2024-08-01 | Ideaya Biosciences Inc | Combined treatment that includes a fax inhibitor and a c-met inhibitor |
| EP4504780A1 (en) | 2022-04-01 | 2025-02-12 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
| KR20250008898A (ko) | 2022-05-11 | 2025-01-16 | 제넨테크, 인크. | 항-fcrh5/항-cd3 이중특이성 항체로 치료하기 위한 투약법 |
| CN119856056A (zh) | 2022-06-07 | 2025-04-18 | 基因泰克公司 | 用于确定包括抗pd-l1拮抗剂和抗tight拮抗剂抗体的肺癌治疗的疗效的方法 |
| KR20250039386A (ko) | 2022-07-13 | 2025-03-20 | 제넨테크, 인크. | 항-fcrh5/항-cd3 이중특이적 항체를 이용한 치료를 위한 투약법 |
| JP2025523845A (ja) | 2022-07-19 | 2025-07-25 | ジェネンテック， インコーポレイテッド | 抗ｆｃｒｈ５／抗ｃｄ３二重特異性抗体による処置のための投薬 |
| CN120153254A (zh) | 2022-09-01 | 2025-06-13 | 基因泰克公司 | 膀胱癌的治疗和诊断方法 |
| WO2024067631A1 (zh) * | 2022-09-30 | 2024-04-04 | 应世生物科技(南京)有限公司 | Fak抑制剂及诱导免疫原性细胞死亡的物质的药物组合及用途 |
| EP4599089A1 (en) | 2022-10-05 | 2025-08-13 | Genentech, Inc. | Methods and compositions for classifying and treating bladder cancer |
| WO2024077166A1 (en) | 2022-10-05 | 2024-04-11 | Genentech, Inc. | Methods and compositions for classifying and treating lung cancer |
| TW202426505A (zh) | 2022-10-25 | 2024-07-01 | 美商建南德克公司 | 癌症之治療及診斷方法 |
| KR20250122520A (ko) | 2022-12-20 | 2025-08-13 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 rna 백신을 이용한 췌장암 치료 방법 |
| WO2024233341A1 (en) | 2023-05-05 | 2024-11-14 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
| WO2024233646A1 (en) | 2023-05-10 | 2024-11-14 | Genentech, Inc. | Methods and compositions for treating cancer |
| WO2024263195A1 (en) | 2023-06-23 | 2024-12-26 | Genentech, Inc. | Methods for treatment of liver cancer |
| WO2024263904A1 (en) | 2023-06-23 | 2024-12-26 | Genentech, Inc. | Methods for treatment of liver cancer |
| WO2025024257A1 (en) | 2023-07-21 | 2025-01-30 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| WO2025049277A1 (en) | 2023-08-25 | 2025-03-06 | Genentech, Inc. | Methods and compositions for treating non-small cell lung cancer comprising an anti-tigit antagonist antibody and a pd-1 axis binding antagonist |
| WO2025085404A1 (en) | 2023-10-16 | 2025-04-24 | Genentech, Inc. | Diagnostic and therapeutic methods for treating lung cancer |
| WO2025155607A1 (en) | 2024-01-16 | 2025-07-24 | Genentech, Inc. | Methods of treating urothelial carcinoma with a pd-1 axis binding antagonist and an rna vaccine |
| WO2025174933A1 (en) | 2024-02-14 | 2025-08-21 | Genentech, Inc. | Methods for treatment of pancreatic cancer with anti-pd-l1 ab, anti-tigit ab, gemcitabine and nab-placlitaxel |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| KR100483494B1 (ko) | 1998-12-01 | 2005-04-15 | 프로테인 디자인 랩스 인코포레이티드 | 감마 인터페론에 대한 인간화 항체 |
| US7141581B2 (en) | 1999-07-02 | 2006-11-28 | Agouron Pharmaceuticals, Inc. | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
| TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| EP2243493A1 (en) | 2002-07-03 | 2010-10-27 | Ono Pharmaceutical Co., Ltd. | Immunopotentiative composition |
| BR0316880A (pt) | 2002-12-23 | 2005-10-25 | Wyeth Corp | Anticorpos contra pd-1 e usos dos mesmos |
| US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
| EP1613320A1 (en) | 2003-04-03 | 2006-01-11 | Pfizer Inc. | Dosage forms comprising ag013736 |
| NZ552946A (en) | 2004-08-26 | 2010-09-30 | Pfizer | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors |
| ES2341351T3 (es) | 2004-08-26 | 2010-06-18 | Pfizer, Inc. | Compuestos de aminoheteroarilo enantiomericamente puros como inhibidores de proteina cinasas. |
| CN101094836A (zh) | 2004-11-02 | 2007-12-26 | 辉瑞大药厂 | 制备吲唑化合物的方法 |
| WO2006048745A1 (en) | 2004-11-02 | 2006-05-11 | Pfizer Inc. | Methods for preparing indazole compounds |
| RU2007116150A (ru) | 2004-11-02 | 2008-11-10 | Пфайзер Инк. (US) | Полиморфные формы 6-[2-(метилкарбамоил)фенилсульфанил]-3-е-[2-[пиридин-2-ил)этенил]индазола |
| CN101052633A (zh) | 2004-11-02 | 2007-10-10 | 辉瑞大药厂 | 制备吲唑化合物的方法 |
| KR20070058690A (ko) | 2004-11-02 | 2007-06-08 | 화이자 인코포레이티드 | 인다졸 화합물의 제조방법 |
| CA2970873C (en) | 2005-05-09 | 2022-05-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| WO2006123223A1 (en) | 2005-05-19 | 2006-11-23 | Pfizer Inc. | Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor |
| EA019344B1 (ru) | 2005-07-01 | 2014-03-31 | МЕДАРЕКС, Эл.Эл.Си. | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения |
| AU2006323027B2 (en) | 2005-12-05 | 2012-08-02 | Pfizer Products Inc | Method of treating abnormal cell growth |
| NZ568289A (en) | 2005-12-05 | 2011-06-30 | Pfizer Prod Inc | Polymorphs of (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1- piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine |
| ES2635724T3 (es) | 2007-03-29 | 2017-10-04 | Cellutech Ab | Material de celulosa de nanopartículas magnéticas |
| WO2008122858A2 (en) | 2007-04-05 | 2008-10-16 | Pfizer Products Inc. | Crystalline forms of 6- [2- (methylcarbamoyl) phenylsulfanyl] -3-e- [2- (pyridin-2-yl) ethenyl] indazole suitable for the treatment of abnormal cell growth in mammals |
| SI2170959T1 (sl) | 2007-06-18 | 2014-04-30 | Merck Sharp & Dohme B.V. | Protitelesa proti receptorjem pd-1 za humano programirano smrt |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| EA201170375A1 (ru) | 2008-08-25 | 2012-03-30 | Эмплиммьюн, Инк. | Антагонисты pd-1 и способы их применения |
| BRPI0919377A2 (pt) | 2008-09-26 | 2016-09-27 | Dana Farber Cancer Inst Inc | anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento |
| FI4209510T3 (fi) | 2008-12-09 | 2024-03-22 | Hoffmann La Roche | Anti-PD-L1-vasta-aineita ja niiden käyttö T-solutoiminnan tehostamiseksi |
| JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害 |
| PH12013500395B1 (en) | 2010-09-09 | 2020-10-16 | Pfizer | 4-1bb binding molecules |
| PL2691112T3 (pl) * | 2011-03-31 | 2018-09-28 | Merck Sharp & Dohme Corp. | Stabilne preparaty przeciwciał przeciw ludzkiemu receptorowi programowanej śmierci pd-1 i terapie powiązane |
| ES2724801T3 (es) | 2011-04-19 | 2019-09-16 | Pfizer | Combinaciones de anticuerpos anti-4-1BB y anticuerpos inductores de ADCC para el tratamiento del cáncer |
| TW202114735A (zh) | 2011-08-01 | 2021-04-16 | 美商建南德克公司 | 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法 |
| RU2014102935A (ru) | 2011-08-02 | 2015-09-10 | Пфайзер Инк. | Кризотиниб для применения в лечении рака |
| AU2013201121A1 (en) * | 2011-09-20 | 2013-04-04 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| TW201328725A (zh) | 2011-09-30 | 2013-07-16 | Pfizer | Ｎ－甲基－２－［３－（（ｅ）－２－吡啶－２－基－乙烯基）－１ｈ－吲唑－６－基硫烷基］苯甲醯胺之藥學組成物 |
| RU2014116407A (ru) | 2011-11-11 | 2015-12-20 | Пфайзер Инк. | N-метил-2-[3-((e)-2-пиридин-2-ил-винил)-1н-индазол-6-илсульфанил]-бензамид для лечения хронического миелоидного лейкоза |
| AR093984A1 (es) * | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| US20160084839A1 (en) * | 2013-04-02 | 2016-03-24 | Marisa Dolled-Filhart | Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue |
| US20170175197A1 (en) * | 2014-01-29 | 2017-06-22 | Caris Mpi, Inc. | Molecular profiling of immune modulators |
| EP3185866A1 (en) * | 2014-08-25 | 2017-07-05 | Pfizer Inc. | Combination of a pd-1 antagonist and an alk inhibitor for treating cancer |
| US20180282415A1 (en) * | 2015-09-30 | 2018-10-04 | Merck Patent Gmbh | Combination of a PD-1 Axis Binding Antagonist and an ALK Inhibitor for Treating ALK-Negative Cancer |
-
2015
- 2015-08-24 EP EP15757408.8A patent/EP3185866A1/en not_active Withdrawn
- 2015-08-24 US US15/506,316 patent/US10695426B2/en active Active
- 2015-08-24 CA CA2955676A patent/CA2955676A1/en not_active Abandoned
- 2015-08-24 WO PCT/US2015/046477 patent/WO2016032927A1/en not_active Ceased
- 2015-08-24 JP JP2017511242A patent/JP2017530950A/ja not_active Withdrawn
-
2020
- 2020-04-03 JP JP2020067185A patent/JP2020117524A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017530950A5 (enExample) | ||
| JP2017506227A5 (enExample) | ||
| JP2018512391A5 (enExample) | ||
| RU2016109811A (ru) | Лечение рака комбинацией антагониста pd-1 и динациклиба | |
| Jensen et al. | Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer | |
| Reck et al. | Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) | |
| Landes et al. | The efficacy of selinexor (KPT-330), an XPO1 inhibitor, on non-hematologic cancers: a comprehensive review | |
| MX2016008362A (es) | Combinaciones farmaceuticas. | |
| IL278423B2 (en) | Pd-1 / pd-l1 inhibitors for the treatment of cancer | |
| WO2017097723A3 (en) | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies | |
| RU2018101314A (ru) | Комбинированные способы лечения антагонистами pd-l1 | |
| JP2019506403A5 (enExample) | ||
| MX2018015353A (es) | Usos terapeuticos de un inhibidor de c-raf. | |
| JP2017537070A5 (enExample) | ||
| RU2016146993A (ru) | Комбинация антитела к CCR4 и агониста 4-1BB для лечения рака | |
| RU2017117664A (ru) | Комбинация | |
| IL292193B2 (en) | Anti-b7-h1 antibodies for treating tumors | |
| JP2016533366A5 (enExample) | ||
| EA201692285A8 (ru) | Ингибиторы ezh2 для лечения лимфомы | |
| GEP20237479B (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | |
| MA39070A1 (fr) | Anticorps anti-cd38 spécifiques pour le traitement de cancers humains | |
| MX2020006042A (es) | Metodos de tratamiento de cancer de colon usando terapia combinada de inhibidor del objetivo mamifero de la rapamicina (mtor) en nanoparticulas. | |
| JP2018524347A5 (enExample) | ||
| AU2018335617B2 (en) | Combination of a BTK inhibitor and an inhibitor of CDK9 to treat cancer | |
| JP2018508516A5 (enExample) |